Suven Life secures product patents for their NCEs in Europe

Suven Life Sciences Ltd., receives two product patents for their NCEs (New Chemical Entities) in Europe


Suven Life Sciences Ltd (Suven), Hyderabad, recently announced the grant of two (2) product patents from Europe (1567492 and 2346847), corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases. These Patents are valid through 2023 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with Neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson's disease and Schizophrenia.

With these new patents, Suven has a total of thirteen (13) granted patents from Europe. These granted patents is said to be an exclusive intellectual property of Suven and were achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (Central Nervous System) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR (G-protein-coupled receptors) targets.

The Company has twelve (12) internally-discovered therapeutic drug candidates, currently in the pre-clinical stage of development targeting conditions, such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email